Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.

Background: Endoscopic mucosal healing is an established treatment target for UC, yet the value of achieving histological remission remains unclear.

Aims: To evaluate histological remission compared to endoscopic mucosal healing for predicting patient outcomes in UC.

Methods: Blinded assessment of endoscopic and histological measures of disease activity was performed on patients with established UC at baseline.

Postpolypectomy haemorrhage following removal of large polyps using mechanical haemostasis or epinephrine: a meta-analysis.

Background And Aim: Postpolypectomy haemorrhage (PPH) is a known adverse event that can occur following polypectomy, occurring in 0.3-6.1% of cases.

Colon salvage therapy for acute severe colitis: cyclosporine or infliximab?

Purpose Of Review: Steroid-refractory acute severe colitis (ASC) poses a significant clinical challenge to both physicians and surgeons alike. This review highlights advances in management of these patients and the role of cyclosporine compared to infliximab.

Recent Findings: ASC affects 25% of patients with ulcerative colitis and is associated with measurable morbidity and mortality.

Anti-tumour necrosis factor-alpha treatment for perianal Crohn's disease in Australia.

Objective: To examine the prevalence of perianal Crohn's disease (PCD) and the eligibility of PCD patients to access anti-tumour necrosis factor-alpha (anti-TNFalpha) treatment under current Australian Pharmaceutical Benefits Scheme (PBS) guidelines.

Design, Setting And Participants: A retrospective study of patients with Crohn's disease (CD) and PCD attending four large adult inflammatory bowel disease (IBD) centres in Australia between January 2004 and May 2008. Patients for whom anti-TNFalpha therapy was clinically indicated were assessed to determine whether they satisfied PBS criteria for subsidised medication.